Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the period of May 2018, specifically dated May 25, 2018. The filing discloses the entry into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. to facilitate an "at the market" offering of ordinary shares.
Key Financial Metrics
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data points relate to the proposed capital raise:
- Maximum Offering Size: Up to $25 million in aggregate offering price.
- Commission Rate: 3.0% of aggregate gross proceeds payable to the sales agent.
- Expense Reimbursement Cap: Up to $50,000 for specified expenses related to the agreement.
Material Changes
The material change disclosed is the authorization of a new equity financing mechanism. The Company may now sell ordinary shares through Cantor Fitzgerald & Co. on the Nasdaq Global Market or other existing trading markets, subject to price designations set by the Company. This utilizes a shelf registration statement (File No. 333-213007) previously declared effective on October 11, 2016.
Guidance, Outlook, and Risks
Management Commentary: The Company retains discretion over sales, including the ability to instruct the agent not to sell shares if they cannot be effected at or above a designated price. The Company is not obligated to make any sales under the agreement.
Risks and Contingencies: The offering is subject to termination by either the Company or Cantor Fitzgerald & Co. as permitted in the Sales Agreement. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $25 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses and price floor mechanisms.
- Confirm the status of the underlying shelf registration statement (File No. 333-213007).
- Assess the Company's current cash position to determine the urgency of this financing.